In 2018, the industry saw a surge in new approvals in chemical entities and new biologic drugs, driven by novel science and the FDA’s new guidance to accelerate the approval process.
More than half of the new approvals were for rare diseases.
In 2017, the FDA approved 46 drugs, which matched the record in 2015.
More articles on supply chain:
FDA to modernize medical device approval process: 5 things to know
First FDA-cleared ‘digital therapeutic’ for substance use disorder launches
3 digital health moves the FDA made in 2018
